Population pharmacokinetics of glyburide in patients with well-controlled diabetes.
OBJECTIVE
To investigate glyburide pharmacokinetics in patients with well-controlled noninsulin-dependent diabetes mellitus (NIDDM), and test the hypothesis that intersubject variability in the glyburide dose is due to patient differences in the drug's pharmacokinetics.


METHODS
Prospective, open-label study.


METHODS
University-affiliated, internal medicine outpatient clinic.


METHODS
Fifty-one patients with NIDDM (11 women, 40 men, mean age 56.7 +/- 15.3 yrs) receiving oral glyburide and with well-controlled glycohemoglobin levels 10.0% or below.


METHODS
After fasting overnight, patients ingested their regular morning dose of glyburide and then ate breakfast. Blood samples were drawn before dosing and between 0.5-2 hours, 2-5 hours, and 5-10 hours after dosing.


RESULTS
Serum glyburide was assayed by high-performance liquid chromatography and pharmacokinetics by NONMEM. Glyburide clearance was proportional to weight and greater in older patients (> 60 yrs).


CONCLUSIONS
Variability in the glyburide dose was not primarily due to intersubject differences in the drug's pharmacokinetics.
Tracewell
W G
WG
Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha 68198-6025, USA.
Stalker
D J
DJ
Maloley
P A
PA
Gallagher
T F
TF
Gwilt
P R
PR
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001682:Biological Availability; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000378:metabolism*; D005260:Female; D005905:Glyburide / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D011446:Prospective Studies
D007004:Hypoglycemic Agents; D005905:Glyburide